preamble_8
Whereas the experience acquired as a result of Directive 87/22/EEC has shown that it is necessary to establish a centralized Community authorization procedure for technologically advanced medicinal products, in particular those derived from biotechnology; whereas this procedure should also be available to persons responsible for placing on the market medicinal products containing new active substances which are intended for use in human beings or in food-producing animals;
← preamble_7 · All articles · preamble_9 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.